These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 3578323)

  • 1. In vitro activity of ciprofloxacin against gram-positive cocci.
    Barry AL; Jones RN
    Am J Med; 1987 Apr; 82(4A):27-32. PubMed ID: 3578323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of ciprofloxacin against gram-positive bacteria. An overview.
    Kayser FH; Novak J
    Am J Med; 1987 Apr; 82(4A):33-9. PubMed ID: 3555058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [In vitro activity of vancomycin and teicoplanin against gram-positive cocci].
    Bezian MC; Ribou G; Masquelier B
    Pathol Biol (Paris); 1992 May; 40(5):461-5. PubMed ID: 1386667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of preclinical studies with ciprofloxacin.
    Sanders CC; Sanders WE; Goering RV
    Am J Med; 1987 Apr; 82(4A):2-11. PubMed ID: 3646829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
    Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
    Cafini F; Aguilar L; González N; Giménez MJ; Torrico M; Alou L; Sevillano D; Vallejo P; Prieto J
    J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spectrum of activity, mutation rates, synergistic interactions, and the effects of pH and serum proteins for fusidic acid (CEM-102).
    Biedenbach DJ; Rhomberg PR; Mendes RE; Jones RN
    Diagn Microbiol Infect Dis; 2010 Mar; 66(3):301-7. PubMed ID: 20159376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of levofloxacin against coagulase-positive and -negative staphylococci.
    Cafiso V; Messina C; Santagati M; Campanile F; Bonfiglio G; Stefani S
    Drugs Exp Clin Res; 2001; 27(3):107-11. PubMed ID: 11447768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
    Sader HS; Watters AA; Fritsche TR; Jones RN
    BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Susceptibility of methicillin-sensitive and methicillin-resistant staphylococci to ciprofloxacin].
    Namysł E; Piechowicz L; Krzywińska E; Galiński J
    Med Dosw Mikrobiol; 1993; 45(2):149-52. PubMed ID: 8309287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of pefloxacin against gram-negative and gram-positive bacteria in comparison with other antibiotics.
    Debbia E; Schito GC; Nicoletti G; Speciale A
    Chemioterapia; 1987 Oct; 6(5):319-23. PubMed ID: 3480779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the in vitro antibacterial activity of teicoplanin and vancomycin against gram-positive cocci.
    Ravizzola G; Pirali F; Foresti I; Turano A
    Drugs Exp Clin Res; 1987; 13(4):225-9. PubMed ID: 2957187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.
    Draghi DC; Benton BM; Krause KM; Thornsberry C; Pillar C; Sahm DF
    J Antimicrob Chemother; 2008 Jul; 62(1):116-21. PubMed ID: 18424792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens.
    Streit JM; Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 Dec; 53(4):307-10. PubMed ID: 15922534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Sensitivity of methicillin resistant staphylococci to linezolid and some other antimicrobial agents].
    Ertek M; Yazgi H; Aktaş E; Ayyildiz A; Parlak M
    Mikrobiyol Bul; 2003 Oct; 37(4):235-40. PubMed ID: 14748259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci.
    Fass RJ
    Antimicrob Agents Chemother; 1991 Mar; 35(3):553-9. PubMed ID: 1903912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibacterial activity of teicoplanin and vancomycin in combination with rifampicin, fusidic acid or fosfomycin against staphylococci on vein catheters.
    Simon VC; Simon M
    Scand J Infect Dis Suppl; 1990; 72():14-9. PubMed ID: 2151061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis on the susceptibility of fusidic acid for common gram positive bacteria].
    Liu C; Wang ZQ; Li R; Sun XG
    Zhonghua Yan Ke Za Zhi; 2009 May; 45(5):452-5. PubMed ID: 19576070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of sparfloxacin (AT-4140 and CI-978), a new quinolone antimicrobial agent, against Haemophilus and gram-positive cocci.
    Rudrik JT; Ferrigno SR; Gee SL
    Diagn Microbiol Infect Dis; 1991; 14(4):355-60. PubMed ID: 1889186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of Scandinavian in vitro studies with ciprofloxacin.
    Forsgren A
    Scand J Infect Dis Suppl; 1989; 60():16-22. PubMed ID: 2667106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.